A non-replicating oncolytic vector as a novel therapeutic tool against cancer

BMB Reports

Volumn 43, Issue 12, 2010, Pages 773-780

  Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Anti tumor immunity; Apoptosis; Cancer; Gene therapy; HVJ

Indexed keywords

ONCOLYTIC VIRUS;

GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; NATURAL KILLER CELL; NEOPLASM; REVIEW; SENDAI VIRUS; T LYMPHOCYTE;

GENE THERAPY; GENETIC VECTORS; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; ONCOLYTIC VIRUSES; SENDAI VIRUS; T-LYMPHOCYTES;

SENDAI VIRUS;

EID: 78650699843     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2010.43.12.773     Document Type: Review

References (52)

1. Moon, C., Oh, Y. and Roth, J.A. (2003) Current status of gene therapy for lung cancer and head and neck cancer. Clin. Cancer Res. 9, 5055-5067.
2. Fujiwara, T., Tanaka, N., Kanazawa, S., Ohtani, S., Saijo, Y., Nukiwa, T., Yoshimura, K., Sato, T., Eto, Y., Chada, S., Nakamura, H. and Kato, H. (2006) Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 1689-1699.
3. O'Neill, D. and Bhardwaj, N. (2005) Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol. Med. 109, 1-18.
4. Kim, R., Emi, M. and Tanabe, K. (2006) Cancer immunosuppression and autoimmune disease: beyond immunosuppressive network for tumor immunity. Immunology 119, 254-264.
5. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F., Wunderlich, J., Restifo, N.P., Thomasian, A., Downey, S.G., Smith, F.O., Klapper, J., Morton, K., Laurencot, C., White, D.E. and Rosenberg, S.A. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239.
6. Kirkwood, J.M., Tarhini, A.A., Panelli, M.C., Moschos, S.J., Zarour, H.M., Butterfield, L.H. and Gogas, H.J. (2008) Next generation of immunotherapy for melanoma. J. Clin. Oncol. 20, 3445-3455.
7. Samuel, M., Chow, P.K., Chan, Shih-Yen, E., Machin, D. and Soo, K.C. (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Database Syst. Rev. Jan. 21(1), CD001199.
8. Kelly, E. and Russell, S.J. (2007) History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659.
9. Liu, T.C. and Kirn, D. (2008) Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15, 877-884.
10. Kirn, D.H. and Thorne, S.H. (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9, 64-71.
11. Kaneda, Y., Nakajima, T., Nishikawa, T., Yamamoto, S., Ikegami, H., Suzuki, N., Nakamura, H., Morishita, R. and Kotani, H. (2002) HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system. Mol. Ther. 6, 219-226.
12. Kaneda, Y. (2010) Update on non-viral delivery methods for cancer therapy; possibilities of DDS with anti-cancer activities beyond delivery as a new therapeutic tool. Expert Opinion Drug Delivery 9, 1079-1093.
13. Okada, Y. (1993) Sendai virus-induced cell fusion; in Methods in Enzymology volume 221, Duzgunes N, (ed.). pp 18-41. Academic Press, Inc., San Diego, USA.
14. Kaneda, Y., Saeki, Y. and Morishita, R. (1999) Gene therapy using HVJ-liposomes; the best of both worlds. Mol. Med. Today 5, 298-303.
15. Kaneda, Y. (2008) Applications on hemagglutinating virus of Japan in therapeutic delivery system. Expert Opinion Drug Delivery 5, 221-233.
16. Kaneda, Y., Nakajima, T. and Yamamoto, S. (2005) Development of HVJ envelope vector and its application to gene therapy. Adv. Genet. 53PA, 307-332.
17. Kurooka, M. and Kaneda, Y. (2007) Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 67, 227-236.
18. Fujihara, A., Kurooka, M., Miki, T. and Kaneda Y. (2008) Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol. Immunother. 57, 73-84.
19. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036.
20. Lal, G., Zhang, N., van der Touw, W., Ding, Y., Ju, W., Bottinger, E.P., Reid, S.P., Levy, D.E. and Bromberg, J.S. (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182, 259-273.
21. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Sousa, C.R., Matsuura, Y., Fujita, T. and Akira, S. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105.
22. Seth, R.B., Sun, L., Ea, C.K. and Chen, Z.J. (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669-682.
23. Tang, E.D. and Wang, C.Y. (2010) TRAF5 is a downstream target of MAVS in antiviral innate immune signaling. PLoS One 5(2), e9172.
24. Suzuki, H., Kurooka, M., Hiroaki, Y., Fujiyoshi, Y. and Kaneda, Y. (2008) Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Letter 582, 1325-1329.
25. Kawaguchi, Y., Miyamoto, Y., Inoue, T. and Kaneda, Y. (2009) Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 124, 2478-2487.
26. Sadler, J. and Williams, B.R.G. (2008) Interferon-inducible antiviral effects. Nat. Rev. Immunology. 8, 559-568.
27. Platanias, L.C. and Fish, E.N. (1999) Signaling pathways activated by interferons. Exp. Hematol. 11, 1583-1592.
28. Tanaka, M., Shimbo, T., Kikuchi, Y., Matsuda, M. and Kaneda, Y. (2010) Sterile alpha motif containing domain 9 (SAMD9) is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int. J. Cancer 126, 1982-1991.
29. Ito, M., Yamamoto, S., Nimura, K., Hiraoka, K., Tamai, K. and Kaneda, Y. (2005) Rad51 siRNA delivered by HVJ envelope vector enhances the anticancer effect of cisplatin J. Gene Med. 7, 1044-1052.
30. Blangy, A., Lane, H.A., d'Hérin, P., Harper, M., Kress, M. and Nigg, E.A. (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83, 1159-1169.
31. Matsuda, M., Yamamoto, T., Matsumura, A. and Kaneda, Y. (2009) Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Ther. 16, 1465-1476.
32. Lefranc, F., Cool, V., Velu, T., Brotchi, J. and De Witte, O. (2002) Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9 L rat gliosarcoma model. Int. J. Oncol. 20, 1077-1085.
33. Pan, D., Wei, X., Liu, M., Feng, S., Tian, X., Feng, X. and Zhang, X. (2009) Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells. Neurol. Res. doi: 10.1179/174313209X455736.
34. Natsume, A., Mizuno, M., Ryuke, Y. and Yoshida, J. (1999) Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. 6, 1626-1633.
35. Meijer, D.H., Maguire, C.A., LeRoy, S.G. and Sena-Esteves, M. (2009) Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther. 16, 664-671.
36. Glick, R.P., Lichtor, T., de Zoeten, E., Deshmukh, P. and Cohen, E. P (1999) Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45, 867-874.
37. Iwadate, Y., Inoue, M., Saegusa, T., Tokusumi, Y., Kinoh, H., Hasegawa, M., Tagawa, M., Yamaura, A., Shimada, H. (2005) Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin. Cancer Res. 11, 3821-3827.
38. Liu, Y., Ehtesham, M., Samoto, K., Wheeler, C.J., Thompson, R.C., Villarreal, L.P., Black, K.L. and Yu, J.S. (2002) In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 9, 9-15.
39. Hellums, E.K., Markert, J.M., Parker, J.N., He, B., Perbal, B., Roizman, B., Whitley, R.J., Langford, C.P., Bharara, S. and Gillespie, G.Y. (2005) Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro. Oncol. 7, 213-224.
40. Matsuda, M., Nimura, K., Shimbo, T., Hamasaki, T., Yamamoto, T., Matsumura, A. and Kaneda, Y. (2010) Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J. Neurooncol. In press.
41. Malek, T.R. and Bayer, A.L. (2004) Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4, 665-674.
42. Furtado, G.C., Curotto de Lafaille, M.A., Kutchukhidze, N. and Lafaille, J.J. (2002) Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196, 851-857.
43. Kawachi, M., Tamai, K., Saga, K., Yamazaki, T., Fujita, H., Shimbo, T., Nimura, K., Nishifuji, K., Amagai, M., Uitto, J. and Kaneda, Y. (2007) Development of tissue-targeting HVJ envelope vector for successful delivery of therapeutic gene to mouse skin. Hum. Gene Ther. 18, 881-894.
44. Shimbo, T., Kawachi, M., Saga, K., Fujita, H., Yamazaki, T., Tamai, K. and Kaneda, Y. (2007) Development of a transferrin receptor-targeting HVJ-E vector. Biochem. Biophys. Res. Comm. 364, 423-428.
45. Saga, K., Tamai, K., Kawachi, M., Shimbo, T., Fujita, H., Yamazaki, T. and Kaneda, Y. (2008) Functional modification of Sendai virus by siRNA. J. Biotechnol. 133, 386-394.
46. Kircheis, R. and Wagner, E. (2005) Transferrin receptortargeted gene delivery systems; in Polymeric Gene Delivery Amiji, M.M. (ed.), pp 537-556. CRC Press LLC, Florida, USA.
47. Sudimack, J. and Lee, R.J. (2000) Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41, 147-162.
48. Morris, J.C. and Waldmann, T.A. (2009) Antibody-based therapy of leukaemia. Expert Rev. Mol. Med. 11, e29.
49. Vallera, D. A, Chen, H., Sicheneder, A.R., Panoskaltsis-Mortari, A. and Taras, E.P. (2009) Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk. Res. 33, 1233-1242.
50. van Waarde, A., Rybczynska, A. A, Ramakrishnan, N., Ishiwata, K., Elsinga, P.H. and Dierckx, R.A. (2010) Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr. Pharm. Des. In press.
51. Chono, S., Li, S.D., Conwell, C.C. and Huang, L. (2008) An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control Release 131, 64-69.
52. Clément, V., Dutoit, V., Marino, D., Dietrich, P.Y. and Radovanovic, I. (2009) Limits of CD133 as a marker of glioma self-renewing cells. Int. J. Cancer 125, 244-248.